Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes
Posted inCardiology Diabetes & Endocrinology news

Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes

A sub-analysis of the Harmony Outcomes trial demonstrates that albiglutide consistently reduces major adverse cardiovascular events in Type 2 diabetes patients, irrespective of baseline atrial fibrillation, while showing a trend toward reducing new-onset AF without increasing arrhythmic risk.
Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT
Posted inDiabetes & Endocrinology Internal Medicine news

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT

The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves' hyperthyroidism, suggesting no clinical benefit for routine supplementation.
Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）
Posted inCardiology Diabetes & Endocrinology news

Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）

A post hoc analysis of the SURMOUNT-4 trial reveals that withdrawing tirzepatide leads to significant weight regain and a proportional reversal of improvements in blood pressure, glycemic control, and lipid profiles, reinforcing the necessity for long-term obesity management.
Beyond the Alarm: Does CGM Truly Restore Hypoglycemia Awareness in Older Adults with Type 1 Diabetes?
Posted inDiabetes & Endocrinology Internal Medicine news

Beyond the Alarm: Does CGM Truly Restore Hypoglycemia Awareness in Older Adults with Type 1 Diabetes?

This post hoc analysis of the WISDM study evaluates whether 52 weeks of continuous glucose monitoring (CGM) improves impaired awareness of hypoglycemia (IAH) in older adults. While severe events decreased, physiological awareness remained largely unchanged, revealing critical limitations in current IAH assessment tools.
Narrowing the Equity Gap: The Impact of California’s 2022 Medicaid Expansion on Access to SGLT-2 Inhibitors and GLP-1 RAs in Older Undocumented Immigrants
Posted inClinical Updates Diabetes & Endocrinology news Public Health

Narrowing the Equity Gap: The Impact of California’s 2022 Medicaid Expansion on Access to SGLT-2 Inhibitors and GLP-1 RAs in Older Undocumented Immigrants

This review analyzes the significant shift in type 2 diabetes prescribing patterns following California's 2022 Medi-Cal expansion, highlighting how policy-driven access to SGLT-2 inhibitors and GLP-1 receptor agonists narrowed health equity gaps for older undocumented populations.
Inhaled Insulin for Pediatric Type 1 Diabetes: Analyzing the INHALE-1 Trial Results and Clinical Implications
Posted inDiabetes & Endocrinology news Pediatrics

Inhaled Insulin for Pediatric Type 1 Diabetes: Analyzing the INHALE-1 Trial Results and Clinical Implications

The INHALE-1 trial evaluated inhaled technosphere insulin in children. While it narrowly missed the primary HbA1c noninferiority margin, the study demonstrated improved patient satisfaction, reduced weight gain, and a favorable safety profile, suggesting its potential as a needle-free alternative for select pediatric patients.
Dietary Inflammatory and Insulinemic Potentials Drive Type 2 Diabetes Progression Following Gestational Diabetes: Insights from the Nurses’ Health Study II
Posted inDiabetes & Endocrinology news

Dietary Inflammatory and Insulinemic Potentials Drive Type 2 Diabetes Progression Following Gestational Diabetes: Insights from the Nurses’ Health Study II

A prospective study of 4,318 women reveals that dietary patterns promoting inflammation and hyperinsulinemia significantly elevate the risk of progressing from gestational diabetes to type 2 diabetes, with BMI serving as a primary mediator of this metabolic transition.
Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.
Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
Posted inCardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.